Higher dose of tanezumab meets in latest Phase III pain readout

Pfizer and partner Eli Lilly reported on Feb. 19 that the 10 mg dose of tanezumab met the primary endpoint in the Phase III A4091059 trial to treat chronic low back pain.

The data follow a January readout in which a 5 mg dose of the humanized mAb against nerve growth factor (NGF) met the co-primary endpoints in the Phase III A4091057 trial to treat osteoarthritis pain...